AAAAAA
Results:
1-13
|
Results: 13
Authors:
Kavanaugh, A
Lipsky, P
Citation: A. Kavanaugh et P. Lipsky, Biologics in the treatment of rheumatoid arthritis: Mechanisms of action, CURR DIR AU, 3, 2001, pp. 240-273
Authors:
Wolfe, F
Cush, JJ
O'Dell, JR
Kavanaugh, A
Kremer, JM
Lane, NE
Moreland, LW
Paulus, HE
Pincus, T
Russell, AS
Wilskie, KR
Citation: F. Wolfe et al., Consensus recommendations for the assessment and treatment of rheumatoid arthritis, J RHEUMATOL, 28(6), 2001, pp. 1423-1430
Authors:
Wolfe, F
O'Dell, JR
Kavanaugh, A
Wilske, K
Pincus, T
Citation: F. Wolfe et al., Evaluating severity and status in rheumatoid arthritis, J RHEUMATOL, 28(6), 2001, pp. 1453-1462
Authors:
Kavanaugh, A
Citation: A. Kavanaugh, The utility of immunologic laboratory tests in patients with rheumatic diseases, ARTH RHEUM, 44(10), 2001, pp. 2221-2223
Authors:
Furst, DE
Keystone, EC
Breedveld, FC
Kalden, JR
Smolen, JS
Antoni, CE
Burmester, GR
Crofford, LJ
Kavanaugh, A
Citation: De. Furst et al., Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001), ANN RHEUM D, 60, 2001, pp. III2-III5
Authors:
Shah, M
Coyle, Y
Kavanaugh, A
Adams-Huet, B
Lipsky, PE
Citation: M. Shah et al., Development and initial evaluation of a culturally sensitive cholesterol-lowering diet program for Mexican and African American patients with systemic lupus erythematosus, ARTH C RES, 13(4), 2000, pp. 205-212
Authors:
Kavanaugh, A
St Clair, EW
McCune, WJ
Braakman, T
Lipsky, P
Citation: A. Kavanaugh et al., Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment ofpatients with rheumatoid arthritis receiving methotrexate therapy, J RHEUMATOL, 27(4), 2000, pp. 841-850
Authors:
Kavanaugh, A
Tomar, R
Reveille, J
Solomon, DH
Homburger, HA
Citation: A. Kavanaugh et al., Guidelines for clinical use of the antinuclear antibody test and tests forspecific autoantibodies to nuclear antigens, ARCH PATH L, 124(1), 2000, pp. 71-81
Authors:
Lipsky, PE
Kavanaugh, A
Citation: Pe. Lipsky et A. Kavanaugh, The impact of pharmaco-economic considerations on the utilization of novelanti-rheumatic therapies, RHEUMATOLOG, 38, 1999, pp. 41-44
Authors:
Kavanaugh, A
Citation: A. Kavanaugh, Pharmacoeconomics of emerging therapies for rheumatoid arthritis, AM J M CARE, 5(8), 1999, pp. S483-S488
Authors:
Kavanaugh, A
Citation: A. Kavanaugh, An overview of immunomodulatory intervention in rheumatoid arthritis, DRUGS TODAY, 35(4-5), 1999, pp. 275-286
Authors:
Catchpole, B
Kavanaugh, A
Hobbs, K
Choy, EHS
Citation: B. Catchpole et al., Section 2: Immunomodulatory intervention, DRUGS TODAY, 35(4-5), 1999, pp. 405-406
Authors:
Furst, DE
Breedveld, FC
Burmester, GR
Crofford, L
Emery, P
Feldman, M
Kalden, JR
Kavanaugh, A
Keystone, E
Lipsky, EP
Maini, RN
Moreland, L
Smolen, JS
Van de Putte, L
Smolen, JS
Van de Putte, L
Vischer, T
Weinblatt, M
Weissman, M
Citation: De. Furst et al., Access to disease modifying treatments for rheumatoid arthritis patients, ANN RHEUM D, 58, 1999, pp. 129-130
Risultati:
1-13
|